Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-Be in Remission Study
jRCTs031220473Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Primary endpoint: Molecular remission at Week 12. Started Nov 2022; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs031220473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220473.